 After completing 6 months of imatinib mesylate therapy, you will be randomly assigned as in the toss of a coin to one of two groups. Patients in the first group will be given PEG-Intron and GM-CSF in addition to imatinib mesylate therapy. Patients in the other group will continue taking only imatinib mesylate. 